<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27645381</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2016</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease.</ArticleTitle><Pagination><StartPage>33663</StartPage><MedlinePgn>33663</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">33663</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep33663</ELocationID><Abstract><AbstractText>Hand, Foot and Mouth Disease is a highly contagious disease caused by a range of human enteroviruses. Outbreaks occur regularly, especially in the Asia-Pacific region, putting a burden on public healthcare systems. Currently, there is no antiviral for treating this infectious disease and the only vaccines are limited to circulation in China, presenting an unmet medical need that needs to be filled urgently. The human enterovirus 3&#x2009;C protease has been deemed a plausible drug target due to its essential roles in viral replication. In this study, we designed and synthesized 10 analogues of the Rhinovirus 3&#x2009;C protease inhibitor, Rupintrivir, and tested their 3&#x2009;C protease inhibitory activities followed by a cellular assay using human enterovirus 71 (EV71)-infected human RD cells. Our results revealed that a peptide-based compound containing a trifluoromethyl moiety to be the most potent analogue, with an EC50 of 65&#x2009;nM, suggesting its potential as a lead for antiviral drug discovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Yong Wah</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos #06-05, 138673, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Melgious Jin Yan</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos #03-01, 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Qiu Ying</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos #03-01, 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poulsen</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos #03-01, 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Fui Mee</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos #03-01, 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Then</LastName><ForeName>Siew Wen</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos #03-01, 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Jianhe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos #03-01, 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos #03-01, 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Wan Jin</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos #06-05, 138673, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>Cheng San Brian</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos #03-01, 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Justin Jang Hann</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos #06-05, 138673, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, National University Health System, National University of Singapore 117597, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086042">3C Viral Proteases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086042" MajorTopicYN="N">3C Viral Proteases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27645381</ArticleId><ArticleId IdType="pmc">PMC5028882</ArticleId><ArticleId IdType="doi">10.1038/srep33663</ArticleId><ArticleId IdType="pii">srep33663</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roohandeh A. et al. Frequency of human enterovirus 71 in children under 8 years old with aseptic menengitis in Tehran. Clin Lab 59, 915&#x2013;920 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24133924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Jiang L. &amp; Peng H. L. Clinical Analysis of 134 Children with Nervous System Damage Caused by Enterovirus 71 Infection. Pediatr Infect Dis J 34, 718&#x2013;723 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25860536</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W. et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 9, 8 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268717</ArticleId><ArticleId IdType="pubmed">22230340</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L. D. et al. Correlation analysis of EV71 detection and case severity in hand, foot, and mouth disease in the Hunan Province of China. PLoS One 9, e100003 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4062471</ArticleId><ArticleId IdType="pubmed">24941257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G. et al. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol 85, 10319&#x2013;10331 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F. G. et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 47, 3907&#x2013;3916 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q. M., Johnson R. B., Cox G. A., Villarreal E. C. &amp; Loncharich R. J. A continuous colorimetric assay for rhinovirus-14 3C protease using peptide p-nitroanilides as substrates. Anal Biochem 252, 238&#x2013;245 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9344409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang M. J. et al. Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2-P4 study. J Enzyme Inhib Med Chem, 1&#x2013;8 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25792507</ArticleId></ArticleIdList></Reference><Reference><Citation>Schechter I. &amp; Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27, 157&#x2013;162 (1967).</Citation><ArticleIdList><ArticleId IdType="pubmed">6035483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. et al. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol 85, 10021&#x2013;10030 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Teterina N. L., Gorbalenya A. E., Egger D., Bienz K. &amp; Ehrenfeld E. Poliovirus 2C protein determinants of membrane binding and rearrangements in mammalian cells. J Virol 71, 8962&#x2013;8972 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230196</ArticleId><ArticleId IdType="pubmed">9371552</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho M. W., Teterina N., Egger D., Bienz K. &amp; Ehrenfeld E. Membrane rearrangement and vesicle induction by recombinant poliovirus 2C and 2BC in human cells. Virology 202, 129&#x2013;145 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8009827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienz K., Egger D., Troxler M. &amp; Pasamontes L. Structural organization of poliovirus RNA replication is mediated by viral proteins of the P2 genomic region. J Virol 64, 1156&#x2013;1163 (1990).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249229</ArticleId><ArticleId IdType="pubmed">2154600</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski G. A., Friesner R. A., Tirado-Rives J. &amp; Jorgensen W. L. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides. The Journal of Physical Chemistry B 105, 6474&#x2013;6487 (2001).</Citation></Reference><Reference><Citation>Polak E. &amp; Ribiere G. Note sur la convergence de m&#xe9;thodes de directions conjugu&#xe9;es. Recherche Op&#xe9;rationnelle, S&#xe9;rie Rouge 16, 35&#x2013;43 (1969).</Citation></Reference><Reference><Citation>Hasel W., Hendrickson T. F. &amp; Still W. C. A rapid approximation to the solvent accessible surface areas of atoms. Tetrahedron Computer Methodology 1, 103&#x2013;116 (1988).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>